CureledgerCureledger
ReferencesBlog
Join

Blog

The case for patient-controlled rare disease data across science, policy, and the lived experience.

Featured

Patient Experience

What we still have to do

The structural friction of rare disease daily life.

Read →

This week

Data Sovereignty

Unpaid data farmers

The data work we have been doing for free, finally compensated.

Read →
Vision

The flywheel

Cohort proof licensed. Contribution measured. Deposit lands.

Read →
Science & Data

Cohort proofs

Privacy from cryptography. Validation without exposure.

Read →

Search articles

Browse by tag

Clear ×
Patient ExperienceData SovereigntyVisionScience & DataRegulatoryUltra-rareAccelerating innovationEhlers-DanlosNewborn screeningCompanyHistory
Read all4 of 116 · Tag: Vision
↓
  1. Jul 6, 2026The flywheelVision
  2. Jun 1, 2026It is no longer good business to leave rare diseases behindVision
  3. May 14, 2026The rare disease singularityVision
  4. Apr 22, 2026Cures, Not ManagementVision
About·For investors·Privacy··

© 2026 Cureledger Inc. · Raleigh, NC USA